Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
A high baseline level of soluble human epidermal growth factor receptor 2 (sHER2) was a prognostic indicator of shorter disease-free survival among patients with early-stage HER2-positive breast cancer, according to results from the North Central Cancer Treatment Group adjuvant trial N9831. (Source: Cancer Network)
Source: Cancer Network - June 19, 2013 Category: Cancer & Oncology Source Type: news

RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
The mTOR inhibitor everolimus failed to prove progression-free survival noninferiority compared with the VEGF-targeting tyrosine kinase inhibitor sunitinib when given as first-line treatment in patients with metastatic renal cell carcinoma. (Source: Cancer Network)
Source: Cancer Network - June 19, 2013 Category: Cancer & Oncology Source Type: news

ASCO: PD-L1 Antibody Elicits Durable Response in RCC
Researchers observed durable responses in patients with renal cell carcinoma treated with the PD-L1 antibody MPDL3280A. The study, which was presented at the 2013 ASCO Annual Meeting, was one of the few immune therapy trials that allowed patients with non-clear cell histologies and some clinical activity was observed in these patients. (Source: Cancer Network)
Source: Cancer Network - June 19, 2013 Category: Cancer & Oncology Source Type: news

The Emerging Role of HE4 in the Evaluation of Epithelial Ovarian and Endometrial Carcinomas
In this review, we discuss the discovery and biologic significance of HE4 and evaluate available evidence regarding the utility of HE4 as a biomarker for ovarian and endometrial cancer. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

The Key to Improving Survival in Ovarian Cancer: Better Screening of Women With Vague Symptoms, Leading to Earlier Diagnosis, More Effective Surgery
Although the combination of CA-125 and HE4 appears indicated for use in symptomatic patients or in patients with an adnexal mass, there is no evidence that it would be indicated as a screening test in asymptomatic patients. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

Tailored Therapy in Diffuse Gliomas: Using Molecular Classifiers to Optimize Clinical Management
We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

The Role of Physical Activity in Cancer Prevention, Treatment, Recovery, and Survivorship
This article will review these intersections of exercise and oncology, discuss the known mechanisms by which exercise exerts its salutary effects, and touch upon the future directions of exercise research in the oncology setting. Finally, recommendations are provided for clinicians to help patients with and without cancer take advantage of the benefits of physical activity. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
The use of a yoga program helped to reduce symptoms of insomnia among women with breast cancer undergoing hormonal therapy, and also resulted in an improved quality of life, according to new data presented at ASCO. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

Preventing Burnout in Oncology
Developing an effective personal and professional self-care plan can help oncologists deal with the pressures of caring for terminally ill patients and potentially prevent burnout, a recent study suggests. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
Interim results of a small phase II study found a relatively good response rate with dabrafenib in BRAF V600E mutation-positive stage IV non-small-cell lung cancer (NSCLC) patients. The results were presented at ASCO. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

Metaplastic Mammary Carcinoma With Discrepant Hormone Receptor Results by IHC and RT-PCR
The Case: A 48-year-old perimenopausal woman noted a lump in her left breast. She had had a mammogram 9 months earlier without abnormality. After ultrasound imaging confirmed a solitary mass measuring about 1.5 cm, a core needle biopsy demonstrated a poorly differentiated mammary carcinoma with chondroid features. (Source: Cancer Network)
Source: Cancer Network - June 17, 2013 Category: Cancer & Oncology Source Type: news

Fertility Preservation and Breast Cancer: A Complex Problem
A considerable number of women with breast cancer are diagnosed during their reproductive years. In the short period of time in which newly diagnosed women will need to make decisions about surgical options and adjuvant therapy, younger women with breast cancer also face the potential impairment or complete loss of their fertility. (Source: Cancer Network)
Source: Cancer Network - June 17, 2013 Category: Cancer & Oncology Source Type: news

Postmenopausal Hormone Receptor–Positive Advanced Breast Cancer
The goals of care for patients with hormone receptor (HR)-positive advanced breast cancer include prolongation of disease-free and overall survival, amelioration of symptoms, and improvement in quality of life. (Source: Cancer Network)
Source: Cancer Network - June 17, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Post-Surgery Surveillance Found Safe in Seminoma
Surveillance of patients with stage I seminoma following orchiectomy can spare a majority of patients from adjuvant chemotherapy with a low risk of relapse, according to results presented at the 2013 ASCO meeting. (Source: Cancer Network)
Source: Cancer Network - June 17, 2013 Category: Cancer & Oncology Source Type: news

Bladder Cancer Recurrence High, Better Follow-Up Care Needed
Recent studies suggest patients with bladder cancer are not receiving optimal care or the follow-up surveillance as recommended by the National Comprehensive Cancer Network (NCCN). (Source: Cancer Network)
Source: Cancer Network - June 17, 2013 Category: Cancer & Oncology Source Type: news